by rdbiomed | Mar 14, 2018 | Company News
Peptest will be presented at a key European conference on digestive diseases in Italy this month. The 24th Italian Society of Digestive Diseases Congress (FISMAD 2018) takes place in Rome on 21 to 24 March 2018 at the Ergife Palace Hotel. One of the primary objectives...
by rdbiomed | Mar 8, 2018 | Company News
Professor Peter Dettmar has been working on reflux since 1981 and is a world-leading expert on using the stomach enzyme pepsin as a marker for the disease. In his former role as global R&D Director of Gastrointestinals for Reckitt Benckiser Healthcare, Professor...
by rdbiomed | Feb 28, 2018 | pepsin, reflux
Pepsin can contribute to the pathology of a number of conditions, such as gastro-oesophageal reflux disease (GORD) and laryngopharyngeal reflux (LPR). Peptest is a highly accurate, non-invasive diagnostic test for detecting pepsin in saliva, sputum, and other clinical...
by rdbiomed | Feb 12, 2018 | reflux treatments
Pregnant women who take acid-supressing drugs may be more likely to have children who go on to develop asthma than their counterparts who don’t take these medications, researchers have said. According to recent studies, the overall risk of asthma in childhood...
by rdbiomed | Dec 21, 2017 | reflux treatments
Proton pump inhibitors (PPIs) are used to manage gastro-oesophageal reflux disease symptoms, but many people do not respond well to the medication. The next option is anti-reflux surgery with a variety of endoscopic therapies now available, including STRETTA, MUSE and...
Recent Comments